Akston Biosciences Corp Sample Contracts
INDEMNIFICATION AGREEMENT (for Directors of a Delaware Corporation)Indemnification Agreement • January 15th, 2026 • Akston Biosciences Corp • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of ________________ by and between Akston Biosciences Corporation, a Delaware corporation (the “Company”), and ____________ (“Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 18th, 2026 • Akston Biosciences Corp • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Akston Biosciences Corporation (the “Company”) and _____________________ (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Employment Agreement between the Executive and the Company dated ______ (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
December 15, 2025 James M. Herriman Dear Jim:Transition and Separation Agreement • January 15th, 2026 • Akston Biosciences Corp • Pharmaceutical preparations
On behalf of Akston Biosciences Corporation (the “Company”), this is an amendment to your Transition and Separation Agreement with the Company, dated September 19, 2025, (the “Transition Agreement”) (this amendment, the “Amendment”) to reflect certain changes to the terms of your transition. This Amendment supersedes any prior or contemporaneous agreement, communication or representation with, from or of the Company with respect to the terms described in this Amendment. Otherwise, with respect to all other terms, the Transition Agreement remains in full effect. All capitalized terms not defined herein shall have the meanings ascribed to them in the Transition Agreement.
TERMINATION AGREEMENTTermination Agreement • May 4th, 2026 • Akston Biosciences Corp • Pharmaceutical preparations • Delaware
THIS TERMINATION AGREEMENT (this “Agreement”), is entered into as of April 29, 2026 (the “Termination Date”), by and between Akston Biosciences Corporation, a Delaware corporation (“Akston”) and Diamune Therapeutics, Inc., a Delaware corporation (“Diamune” and, together with Akston, each individually a “Party” and collectively the “Parties”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the License Agreement (as defined below).
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential. AMENDED AND RESTATED LICENSE...License Agreement • October 8th, 2025 • Akston Biosciences Corp • Pharmaceutical preparations • Delaware
Akston Biosciences Corporation, a Delaware corporation having an address of 100 Cummings Center, Suite 454C, Beverly, MA 01915 (hereinafter referred to as “AKSTON”),
To: Shady Grove Road Investments, LLC 106 S. Lafayette StreetLoan Agreement • December 8th, 2025 • Akston Biosciences Corp • Pharmaceutical preparations
We refer to that certain loan agreement dated on or about August 20, 2025 between Borrower and Lender (as amended from time to time, the “Loan Agreement”) and to that certain license agreement between Borrower and Diamune Therapeutics, Inc. (“Diamune”) dated as of June 6, 2025 (as amended from time to time, (“License Agreement”).
UNDERWRITING AGREEMENT between AKSTON BIOSCIENCES CORPORATION and THINKEQUITY LLC as Representative of the Several Underwriters AKSTON BIOSCIENCES CORPORATION UNDERWRITING AGREEMENTUnderwriting Agreement • January 15th, 2026 • Akston Biosciences Corp • Pharmaceutical preparations • New York
The undersigned, Akston Biosciences Corporation, a corporation formed under the laws of the State of Delaware (collectively with its subsidiary and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of Akston Biosciences Corporation, the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
Form of Representative’s Warrant AgreementRepresentative’s Warrant Agreement • January 15th, 2026 • Akston Biosciences Corp • Pharmaceutical preparations
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ____, 2026 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00 p.m. (New York time) on the date that is five (5) years following the Effective Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Akston Biosciences Corporation, a Delaware corporation (the “Company”), up to ______ shares (the “Warrant Shares”) of Common Stock, par value $0.000001 per share, of the Company (the “Common Stock”), as subject to adjustment hereunder. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
September 19, 2025 James M. Herriman Re: Transition and Separation Agreement Dear Jim:Transition and Separation Agreement • October 8th, 2025 • Akston Biosciences Corp • Pharmaceutical preparations • Massachusetts
The purpose of this letter agreement is to confirm the terms of your transition and separation from Akston Biosciences Corporation (“ Akston” or the “Company”). On behalf of the Company’s Board of Directors (the “Board”), thank you for your contributions. We would like to make this transition as smooth as possible. As you are aware, as an “at will” employee, Akston could end your employment relationship at any time and for any reason without additional compensation. Instead, the Board is proposing an agreement that would enable you to remain employed until December 31, 2025 (the “Date of Termination”) and then receive certain Separation Benefits if you satisfy the Conditions (all as defined below). If you do not satisfy any of the Conditions, the Company may end your employment prior to December 31, 2025 and the actual last date of your employment shall be the Date of Termination for purposes of this Agreement.
LOAN AND SECURITY AGREEMENT between SHADY GROVE ROAD INVESTMENTS, LLC as the Lender and AKSTON BIOSCIENCES CORPORATION as the Borrower Dated: August 19, 2025Loan and Security Agreement • December 8th, 2025 • Akston Biosciences Corp • Pharmaceutical preparations • New York
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”), dated as of August 19, 2025 (the “Closing Date”) is made and entered into by and for SHADY GROVE ROAD INVESTMENTS, LLC, a Florida limited liability company (the “Lender”) and AKSTON BIOSCIENCES CORPORATION, a Delaware corporation (the “Borrower”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • October 8th, 2025 • Akston Biosciences Corp • Pharmaceutical preparations
This Exclusive License Agreement (“Agreement”), effective as of June 6, 2025 (the “Effective Date”), is by and between Akston Biosciences Corporation, a Delaware corporation having an address of 100 Cummings Center, Suite 454C, Beverly, MA 01915 (hereinafter referred to as “AKSTON”), and Diamune Therapeutics, Inc., a Delaware corporation having an address at 100 Cummings Center, Suite 455B, Beverly, MA 01915 (hereinafter referred to as “DIAMUNE”),
OPTION AGREEMENTOption Agreement • October 8th, 2025 • Akston Biosciences Corp • Pharmaceutical preparations • Massachusetts
This Option Agreement (the “Agreement”), effective as of August 1st, 2024 (the “Effective Date”), is made by and between Energesis Pharmaceuticals, Inc. (“Energesis”), a business organized and existing under the laws of the State of Delaware, with offices at 700 Main Street, Cambridge, MA 02139, and Akston Biosciences Corporation, a Delaware corporation with offices located at 100 Cummings Center, Suite 454C, Beverly, MA 01915 (“Akston”). Energesis and Akston are referred to herein as a “Party” and collectively as the “Parties.”
OPTION AGREEMENTOption Agreement • October 8th, 2025 • Akston Biosciences Corp • Pharmaceutical preparations • Indiana
THIS OPTION AGREEMENT is made and entered into as of Jume 10, 2024 (“Effective Date”), by and between PURDUE RESEARCH FOUNDATION, a statutory body corporate formed and existing under the Indiana Foundation or Holding Companies Act of 1921, with offices located at 1281 Win Hentschel Blvd, West Lafayette, Indiana 47906 ("PRF") and Akston Biosciences Corporation, a Delaware corporation with offices located at 100 Cummings Center, Suite 454C, Beverly, MA 01915 (“OPTIONEE”) (collectively the “Parties”).
AKSTON BIOSCIENCES CORPORATION REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 15th, 2026 • Akston Biosciences Corp • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 21, 2025, is entered into by and among Akston Biosciences Corporation, a Delaware corporation (the “Company”), and the investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors The Company and the Investors may be referred to herein each as a “Party” and collectively as the “Parties”.
ROYALTY AND REVENUE ASSIGNMENT AGREEMENTRoyalty and Revenue Assignment Agreement • December 8th, 2025 • Akston Biosciences Corp • Pharmaceutical preparations • New York
This Royalty and Revenue Assignment Agreement is dated as of November 7, 2025 (this “Agreement”), by and among Akston Biosciences Corporation, a Delaware corporation (the “Assignor”), and each assignee identified on the signature pages hereto (each, including its successors and assigns, a “Assignee” and collectively the “Assignees”). The Assignor and the Assignees may be referred to herein each as a “Party” and collectively as the “Parties”. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in Article I of this Agreement.
RESTRICTED STOCK AGREEMENT UNDER THE AKSTON BIOSCIENCES CORPORATION 2024 STOCK OPTION AND GRANT PLANRestricted Stock Agreement • July 25th, 2025 • Akston Biosciences Corp • Pharmaceutical preparations • Delaware
Vesting Schedule: [25 percent of the Shares shall vest on the [first] anniversary of the Vesting Commencement Date; provided that the Grantee continues to have a Service Relationship with the Company at such time. Thereafter, the remaining 75 percent of the Shares shall vest in 36 equal monthly installments following the first anniversary of the Vesting Commencement Date, provided the Grantee continues to have a Service Relationship with the Company at such time. Notwithstanding anything in the Agreement to the contrary in the case of a Sale Event, the Shares of Restricted Stock shall be treated as provided in Section 3(c) of the Plan; provided, however, Notwithstanding anything herein to the contrary, in the event that the Shares of Restricted Stock are assumed or continued by the Company or its successor entity in the sole discretion of the parties to a Sale Event and thereafter remain in effect following such Sale Event, then [50% of] the then-unvested Shares shall be deemed vested